Isabelle Newell’s Post

As the implementation of the EU HTA Joint Clinical Assessment (JCA) regulation in 2025 draws nearer, our teams across Value and Access and Evidence Generation have been reflecting on the challenges and opportunities the JCA brings to our industry clients. We will be sharing our reflections each Wednesday over the month of July. First up, our Literature Reviews and Synthesis team has been considering what the new JCA regulation will mean for systematic literature reviews (SLRs), exploring the practical implications for the planning and implementation of SLRs, as well as the potential benefits for the wider scientific community. Read the full article here: https://lnkd.in/eB_WVxVu If you are interested in exploring how our teams could support you with projects in EU HTA, please contact Matthew Griffiths, Global Head of HTA, or Catherine Bunting, Head of Market Access.

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 810+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 870+ market access and HEOR projects in Europe for more than 210 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 870+ market access and HEOR projects in Europe for more than 210 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 870+ market access and HEOR projects in Europe for more than 210 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt